Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLX-PAD intramuscular injections for severe COVID-19 (Phase IIa)
2020-001857-31Phase 2Completed
- Sponsor
- Pluri Inc.
- Start
- Jul 2020
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of PLX-PAD in coronavirus disease 2019 (COVID-19), pneumonia and acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Pluri Inc. Primary endpoint: Ventilator-free days through Day 28. Started Jul 2020; status: completed.
02
Drugs
PLX-PAD
03
Conditions
coronavirus disease 2019 (COVID-19)pneumoniaacute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on 2020-001857-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001857-31.